Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DYN

Dyne Therapeutics Inc

Nov 05 • 04:00PM ET

20.90

-0.62 -2.88 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX CRSP ALNY BMRN RARE NTLA SRPT EDIT BLUE

| Held by: XBI IWM VTI VB VXF IBB IWN SCHA VBR VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.86	Insider Own	22.94%	Shs Outstand	114.34M	Perf Week	-11.55%
Market Cap	2.97B	Forward P/E	-	EPS next Y	-3.40	Insider Trans	0.27%	Shs Float	109.62M	Perf Month	49.82%
Enterprise Value	2.41B	PEG	-	EPS next Q	-0.79	Inst Own	71.78%	Short Float	15.60%	Perf Quarter	86.77%
Income	-412.88M	P/S	-	EPS this Y	-5.82%	Inst Trans	8.97%	Short Ratio	6.10	Perf Half Y	122.34%
Sales	0.00M	P/B	4.18	EPS next Y	4.58%	ROA	-53.11%	Short Interest	17.10M	Perf YTD	-11.29%
Book/sh	5.00	P/C	4.35	EPS next 5Y	6.35%	ROE	-61.32%	52W High	35.68 -41.42%	Perf Year	-27.28%
Cash/sh	4.81	P/FCF	-	EPS past 3/5Y	-4.75% -59.45%	ROIC	-60.05%	52W Low	6.36 228.62%	Perf 3Y	83.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.55% 5.91%	Perf 5Y	6.36%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-7.71%	Oper. Margin	-	ATR (14)	1.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	16.83	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.81	Recom	1.47
Dividend Gr. 3/5Y	- -	Current Ratio	16.83	EPS Q/Q	-38.32%	SMA20	11.15%	Beta	1.31	Target Price	35.80
Payout	-	Debt/Eq	0.21	Sales Q/Q	-	SMA50	35.11%	Rel Volume	0.84	Prev Close	21.52
Employees	191	LT Debt/Eq	0.20	Earnings	Nov 05 AMC	SMA200	67.25%	Avg Volume	2.80M	Price	20.90
IPO	Sep 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.21% -	Trades		Volume	2,361,791	Change	-2.88%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy	$35
Jun-24-25	Initiated	Bernstein	Mkt Perform	$13
Jun-11-25	Resumed	Raymond James	Outperform	$37
Jun-02-25	Resumed	Oppenheimer	Outperform	$34
May-29-25	Initiated	Evercore ISI	Outperform	$46
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Dec-13-24	Initiated	Robert W. Baird	Outperform	$46
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$45
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral	$43 → $35
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15
Oct-12-20	Initiated	Stifel	Buy	$29

Show Previous Ratings

Nov-05-25 04:10PM	Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-03-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +6.78%
Oct-28-25 05:24AM	Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger (Insider Monkey)
Oct-27-25 06:17PM	Why Dyne Therapeutics Stock Crushed the Market on Monday (Motley Fool) +41.18%
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
12:07PM	Loading…
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
Oct-16-25 04:33PM	Dyne's Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year (Insider Monkey)
Oct-06-25 06:01PM	Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +10.28%
Oct-04-25 04:54PM	Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data (Insider Monkey)
Oct-02-25 04:05PM	Dyne Therapeutics Appoints Brian Posner to its Board of Directors (GlobeNewswire)
Sep-29-25 08:35AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire) -5.93%
Sep-10-25 12:20AM	Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating (Insider Monkey)
Aug-27-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
12:13AM	Loading…
Aug-20-25 12:13AM	Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT (Insider Monkey)
Aug-17-25 11:41PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy (Insider Monkey)
Aug-06-25 12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com) +10.70%
Aug-04-25 07:30AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Jul-31-25 09:55AM	Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? (Zacks)
Jul-28-25 04:10PM	Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -6.43%
Jul-16-25 07:00AM	Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer (Business Wire) +12.68%
Jul-11-25 11:27AM	RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT (Insider Monkey)
Jul-02-25 04:01PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Jun-30-25 09:45PM	Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock (GlobeNewswire) -8.82%
04:05PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital (GlobeNewswire)
Jun-24-25 12:46PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101 (Insider Monkey)
Jun-18-25 09:45AM	Dyne at attractive entry point following pullback, says Chardan (TipRanks)
Jun-17-25 07:00AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting (GlobeNewswire) -21.42%
04:05PM	Loading…
Jun-16-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET (GlobeNewswire)
Jun-05-25 07:30AM	Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress (GlobeNewswire)
May-08-25 07:30AM	Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +20.16%
Apr-25-25 05:05AM	EC grants orphan drug designation to Dyne Therapeutics DMD therapy (Pharmaceutical Technology)
Apr-24-25 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +14.20% +6.22%
Apr-15-25 07:30AM	Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments (GlobeNewswire) +5.09%
Apr-14-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -11.76%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer (GlobeNewswire)
04:19PM	Dyne Therapeutics appoints Erick Lucera as CFO (SeekingAlpha)
04:10PM	Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer (GlobeNewswire)
Mar-16-25 07:00PM	Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months (GlobeNewswire)
Mar-12-25 03:05PM	Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks (Benzinga)
01:12PM	BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating (GuruFocus.com)
Mar-11-25 07:30AM	Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum (GlobeNewswire)
Feb-27-25 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-14-25 04:05PM	Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-13-25 09:35AM	After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) (Zacks)
Feb-06-25 09:39AM	Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now (Insider Monkey) +6.89%
Feb-03-25 07:30AM	Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-28-25 09:35AM	Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround (Zacks)
Jan-21-25 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-10-25 06:30AM	Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 (GlobeNewswire) -31.15%
Jan-09-25 07:30AM	Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET (GlobeNewswire) -31.15%
Nov-22-24 06:43AM	Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-12-24 07:30AM	Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:15PM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-09-24 07:30AM	Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases (GlobeNewswire)
Oct-07-24 05:32PM	Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now (Insider Monkey)
Sep-23-24 08:56AM	Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -5.36%
Sep-04-24 09:10AM	Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes (Investor's Business Daily) +5.70%
08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 12:37PM	Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy (Benzinga) -30.70%
06:31AM	Dyne Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
06:30AM	Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts (GlobeNewswire)
Aug-29-24 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-24 10:52PM	DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
05:10PM	Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-29-24 08:50AM	Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why (Zacks)
Jul-18-24 12:00PM	What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now? (Zacks)
Jul-12-24 08:50AM	Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-24-24 07:30AM	Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease (GlobeNewswire)
Jun-13-24 04:40PM	Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-30-24 07:30AM	Dyne Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 07:30AM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
May-21-24 08:39PM	Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock (GlobeNewswire) -7.77%
12:27PM	Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies (Zacks)
07:17AM	Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept (MT Newswires)
May-20-24 05:53PM	Why Is Dyne Therapeutics Stock Soaring On Monday? (Benzinga) +27.82%
04:27PM	Dyne Therapeutics Launches $300 Million Share Offering (MT Newswires)
04:07PM	Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again (Investor's Business Daily)
04:01PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
11:22AM	Update: Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles (MT Newswires)
09:40AM	HC Wainwright Adjusts Price Target on Dyne Therapeutics to $48 From $46, Maintains Buy Rating (MT Newswires)
09:12AM	Sector Update: Health Care Stocks Mixed Pre-Bell Monday (MT Newswires)
08:02AM	Dyne shares jump on trial data for muscle disease drugs (BioPharma Dive)
07:47AM	Dyne Says Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles (MT Newswires)
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:30AM	Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints (GlobeNewswire)
May-19-24 08:00AM	Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET (GlobeNewswire)
May-04-24 05:31AM	Dyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst Projections (GuruFocus.com)
May-02-24 11:52PM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:10PM	Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-30-24 07:32AM	Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target (MT Newswires)
Mar-27-24 04:05PM	Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer (GlobeNewswire) +6.42%

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cox John	CEO & President	Sep 05 '25	Sale	13.41	2,640	35,402	199,539	Sep 09 04:31 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 04 '25	Sale	13.27	894	11,863	95,017	Sep 08 04:06 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 05 '25	Sale	13.41	144	1,931	94,873	Sep 08 04:06 PM
Kerr Douglas	Chief Medical Officer	Sep 04 '25	Sale	13.27	3,552	47,135	89,263	Sep 08 04:03 PM
Kerr Douglas	Chief Medical Officer	Sep 05 '25	Sale	13.41	873	11,707	88,390	Sep 08 04:03 PM
Cox John	Officer	Sep 05 '25	Proposed Sale	13.41	2,640	35,404		Sep 05 04:14 PM
Kerr Douglas	Officer	Sep 04 '25	Proposed Sale	13.27	4,552	60,402		Sep 04 04:45 PM
Cox John	CEO & President	Jul 14 '25	Buy	9.11	100,000	911,000	242,179	Jul 15 05:11 PM
Scalzo Richard William	Officer	Jun 11 '25	Proposed Sale	14.75	1,330	19,619		Jun 11 04:30 PM
Beskrovnaya Oxana	Officer	Jun 11 '25	Proposed Sale	14.75	2,132	31,449		Jun 11 04:29 PM
Cox John	CEO & President	Jun 05 '25	Sale	13.35	4,060	54,201	142,179	Jun 06 04:07 PM
Kerr Douglas	Chief Medical Officer	Jun 05 '25	Sale	13.35	1,342	17,916	92,815	Jun 06 04:05 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Jun 05 '25	Sale	13.35	146	1,949	95,911	Jun 06 04:03 PM
Kerr Douglas	Officer	Jun 05 '25	Proposed Sale	13.35	1,342	17,911		Jun 05 04:13 PM
Cox John	Officer	Jun 05 '25	Proposed Sale	13.35	4,060	54,186		Jun 05 04:11 PM
Scalzo Richard William	Officer	Jun 05 '25	Proposed Sale	13.35	914	12,198		Jun 05 04:09 PM
Beskrovnaya Oxana	Officer	Jun 05 '25	Proposed Sale	13.35	1,093	14,587		Jun 05 04:07 PM
Scalzo Richard William	Officer	May 16 '25	Proposed Sale	11.82	2,479	29,313		May 16 04:10 PM
Beskrovnaya Oxana	Officer	May 16 '25	Proposed Sale	11.82	2,589	30,614		May 16 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Mar 13 '25	Sale	12.12	143	1,733	96,057	Mar 13 04:13 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 11 '25	Sale	11.38	1,343	15,283	122,330	Mar 13 04:08 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 11 '25	Sale	11.38	2,153	24,501	195,840	Mar 13 04:08 PM
Beskrovnaya Oxana	Officer	Mar 11 '25	Proposed Sale	11.38	2,153	24,493		Mar 11 04:09 PM
Scalzo Richard William	Officer	Mar 11 '25	Proposed Sale	11.38	1,343	15,278		Mar 11 04:08 PM
Kerr Douglas	Chief Medical Officer	Mar 05 '25	Sale	11.83	1,343	15,888	94,157	Mar 07 04:08 PM
Cox John	CEO & President	Mar 05 '25	Sale	11.83	4,061	48,042	146,239	Mar 07 04:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 05 '25	Sale	11.83	917	10,848	123,673	Mar 07 04:06 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 05 '25	Sale	11.83	1,094	12,942	197,993	Mar 07 04:04 PM
Kerr Douglas	Officer	Mar 05 '25	Proposed Sale	11.89	1,343	15,968		Mar 05 04:10 PM
Cox John	Officer	Mar 05 '25	Proposed Sale	11.89	4,067	48,356		Mar 05 04:09 PM
Beskrovnaya Oxana	Officer	Mar 05 '25	Proposed Sale	11.89	1,094	13,007		Mar 05 04:08 PM
Scalzo Richard William	Officer	Mar 05 '25	Proposed Sale	11.89	915	10,879		Mar 05 04:07 PM
Beskrovnaya Oxana	Chief Scientific Officer	Feb 18 '25	Sale	13.95	2,598	36,242	199,087	Feb 25 05:09 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 18 '25	Sale	13.95	2,488	34,708	124,590	Feb 18 05:09 PM
Scalzo Richard William	Officer	Feb 18 '25	Proposed Sale	13.91	2,488	34,608		Feb 18 04:15 PM
Beskrovnaya Oxana	Officer	Feb 18 '25	Proposed Sale	13.91	2,598	36,138		Feb 18 04:14 PM
Beskrovnaya Oxana	Chief Scientific Officer	Dec 11 '24	Sale	28.12	2,334	65,632	201,685	Dec 11 08:41 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Dec 11 '24	Sale	28.12	1,455	40,915	127,078	Dec 11 08:40 PM
HIGH SUSANNA GATTI	Officer	Dec 11 '24	Proposed Sale	28.33	5,270	149,299		Dec 11 04:20 PM
Beskrovnaya Oxana	Officer	Dec 11 '24	Proposed Sale	28.33	2,334	66,122		Dec 11 04:19 PM
Scalzo Richard William	Officer	Dec 11 '24	Proposed Sale	28.33	1,455	41,220		Dec 11 04:18 PM
Kersten Dirk	Director	Dec 06 '24	Sale	29.34	101,675	2,983,144	5,434,982	Dec 10 04:05 PM
Kersten Dirk	Director	Dec 09 '24	Sale	29.18	34,437	1,004,872	5,400,545	Dec 10 04:05 PM
Kersten Dirk	Director	Dec 04 '24	Sale	29.39	135,039	3,968,796	5,540,463	Dec 06 04:05 PM
Kersten Dirk	Director	Dec 05 '24	Sale	29.05	3,806	110,564	5,536,657	Dec 06 04:05 PM
Kersten Dirk	Director	Dec 02 '24	Sale	29.67	81,201	2,409,294	5,705,234	Dec 04 04:05 PM
Kersten Dirk	Director	Dec 03 '24	Sale	29.05	29,732	863,715	5,675,502	Dec 04 04:05 PM
McNeill Jonathan	Officer	Nov 25 '24	Proposed Sale	29.69	19,987	593,414		Nov 25 04:11 PM
Forbion Capital Fund IV Cooper	Affiliate	Nov 22 '24	Proposed Sale	30.00	62,301	1,869,030		Nov 22 04:06 PM
Incerti Carlo	Director	Nov 18 '24	Option Exercise	8.69	16,500	143,385	16,500	Nov 18 07:42 PM
Incerti Carlo	Director	Nov 18 '24	Sale	28.73	16,500	474,045	0	Nov 18 07:42 PM
Rhodes Jason P	Director	Nov 14 '24	Sale	33.10	782	25,884	15,962	Nov 18 05:31 PM
Incerti Carlo	Director	Nov 18 '24	Proposed Sale	28.00	16,500	462,000		Nov 18 04:40 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Nov 18 '24	Sale	28.20	2,735	77,127	95,833	Nov 18 04:28 PM
Beskrovnaya Oxana	Chief Scientific Officer	Nov 18 '24	Sale	28.20	2,856	80,539	137,519	Nov 18 04:28 PM
Farwell Wildon	Officer	Nov 18 '24	Proposed Sale	28.39	2,515	71,400		Nov 18 04:13 PM
Scalzo Richard William	Officer	Nov 18 '24	Proposed Sale	28.39	2,735	77,646		Nov 18 04:10 PM
Beskrovnaya Oxana	Officer	Nov 18 '24	Proposed Sale	28.39	2,856	81,081		Nov 18 04:06 PM
McNeill Jonathan	Officer	Nov 18 '24	Proposed Sale	28.39	2,658	75,460		Nov 18 04:05 PM
HIGH SUSANNA GATTI	Officer	Nov 18 '24	Proposed Sale	28.39	2,892	82,103		Nov 18 04:04 PM
Kersten Dirk	Director	Nov 13 '24	Sale	35.24	10,803	380,698	62,301	Nov 15 04:05 PM
Kersten Dirk	Director	Nov 14 '24	Sale	32.82	8,929	293,050	5,786,435	Nov 15 04:05 PM
ForDyne B.V.	Affiliate	Nov 14 '24	Proposed Sale	32.83	1,500,000	49,250,000		Nov 14 04:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DYN

Dyne Therapeutics Inc

Upgrade your FINVIZ experience